Twonovel metabolites, cymbimicins A and B, were isolated from the culture broth of a strain of Micromonospora sp. by screening for cyclophilin binding metabolites from actinomycete strains. Cymbimicin A binds to cyclophilin A with a high affinity six fold lower than to that of cyclosporin A. The binding affinity of cymbimicin B is about 100 times lower. The taxonomy of the producing strain, fermentation, isolation, physical and biological properties and structure elucidation are described.
kmes1}. The goal of this project was to discover novel compounds binding to Cyp A which might act on the same or different pathway than CyA.
Actinomycete strains selected from various environment samples were grown under three different culture conditions and the freeze-dried broths were extracted with methanol. Twelve thousand two hundred four methanol extracts were tested in the solid phase enzymelinked cyclophilin binding assay (CBA)2'3). Three strains showed activity. One of these produced the metabolites cymbimicins A (1) and B (2) . Only cymbimicin A (1) showed high binding activity similar to that of CyA. Despite a similar structure, cymbimicin B (2) shows a 100 times lower binding affinity. In this paper we report on the fermentation, isolation, structure determination and biological properties ofcymbimicin A (1) and B (2).
Materials and Methods

General
Spectral data were recorded on the following instruments: NMR spectra were recorded either on a 893 BRUKER AM-500 or a BRUKER AMX-400 spectrometer. All 2Dexperiments were carried out in phase sensitive modewith time proportional phase increments.
Samples of llmg cymbimicin A in 0.5ml DMSOand 5mg of cymbimicin B in.0.5ml DMSOunder addition of 0.2ml C6D6 were prepared. The addition of C6H6 resulted in a better resolution of the protons in the region between 3.3 and 3.6ppm.
The ID-(1H, 13C) and 2D-spectra (COSY, HSQC, HMBC) of both samples were measured. IR spectra on a FT IR spectrometer BRUKER IFS 66 with KBr, UVspectra on Perkin Elmer Labmda9 spectrometer and MSspectra on a VG-7044SE spectrometer, 8 keV Xenon with nitrobenzyl-alcohol as matrix operating in the FABmode. For the mass spectrometry, the probe was mixed with Lil otherwise no molecular peak was detected.
Taxonomical characterization:
The morphology of the strain was ascertained by light microscopy (Zeiss Axioplan). The analysis of diaminopimelic acid was performed on the hydrolysate of cells grown on Bennett's agar medium.4) The analysis of the fatty acids and the whole-cell sugars was determined by gas chromatography5).
Cyclophilin Binding Assay
The ability of a compoundto bind to cyclophilin was determined by means of a competitive binding assay (cyclophilin binding assay, CBA) as described previously2'^.
Briefly, a D-Lys8-cyclosporin-derivative was coupled to bovine serum albumin (BSA) and coated onto microtiter plate (2//g/ml in phosphate buffered saline (PBS) for 2 hours at 37°C. After saturation of the plate with 2% BSA in PBS (1 hour at 37°C) and washings with 0.05% Tween 20 containing PBS and three times with PBS, biotinylated recombinant cyclophilin A, B or C were incubated overnight at 4°C (75, 50 and 100ng/ml, respectively, in 1%BSA-PBS). After washing, the amount of bound biotinylated cyclophilin was assessed by incubation with a streptavidin coupled to alkaline phosphatase (Jackson Immuno-research Labs, Inc, 1 :6000 in 1%BSA-PBS, 2 hours at 37°C), followed by washing. The absorbance at 405nm was measured after hydrolysis of />-nitro-phenyl phosphate (1 mg/ml in diethanolamine buffer 1m, pH 9.6, for 1~2 hours at 37°C).
In the competitive assay, biotinylated cyclophilins were incubated in the presence of the microbial extracts or compounds (overnight at 4°C). Free cyclosporin A was used as a reference compound. After washingsto remove the unbound cyclophilin, the assay continued as above. Binding of a compound to the biotinylated cyclophilin results in a decrease in the amount of cyclophilin that can bind to the immobilised cyclosporin derivative coated on the plate and thus in a decrease in the final absorbance. The competition obtained in the presence of test compound was calculated as the percent inhibition of the control reaction between cyclophilin and the coated cyclosporin in the absence of inhibitor. Testing serial dilutions of the microbial extracts or the test compound allows determination of the concentration resulting in 50% inhibition of binding of the biotinylated cyclophilin to the immobilized cyclosporin derivative (IC50).
Producing Organism
Cymbimicin A and cymbimicin B are produced by fermenting a strain of the genus Micromonospora sp. A92-313709, which was isolated from a soil sample collected in Bromo, Indonesia. This strain has been deposited at the Deutsche Sammlungvon Mikroorganismen und Zellkulturen, Braunschweig, Germanyunder the accession number DSM8594.
The following taxonomic observations indicate that the strain A92-313709 belongs to the genus Micromonospora. On various agar media, the strain A92-313709 produces single non-motile spores in clusters.
The mycelium is formed of thin hyphae which do not fragment. No aerial mycelium is formed on the traditionally used agar media. Analysis of the cell wall hydrolysates of the strain revealed that the cell walls contained meso-diaminopimelic acid. The fatty acid are iso-and arcte/so-branched, straight and unsaturated and characteristically 1 8 : 0 (stearic acid). The sugar spectrum NOV. 1997 is composed of ribose, arabinose, xylose, mannose, galactose, glucose, meso-inositol. 
Cellular assays
The two-way mouse mixed-lymphocyte reaction and the stimulation of murine spleen cells with concanalavin A were performed according to standard procedures6~8).
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The IL-2 reporter gene assay and the cellular uptake assay have been described elsewhere9' 10*.
Results and Discussion
Structure Elucidation
The IR-spectra of the two compounds are very similar, showing strong absorptions at 3400cm"1 for OH-and NH-vibrations and for C-H bonds at 2967, 2934 and 2877cm"*. The strongcarbonyl absorption at 1787cm" 1 indicates a gammalactoneand the very strong peak at 1653 cm~x is in agreement with peptide linkage. FAB-MS without addition of Lil give no results. Under addition of Lil the molecular ions (M+Li)+ of 1059 resp. 1025 were detected. Together with the elemental analysis, the molecular formula was deduced as C59H92N2O14 for cymbimicin A and C58H86N2O13 for cymbimicin B.
These formula were confirmed from proton and carbon counts by the spectral analysis of^-NMRand 13C-NMR. The NMRspectra show partial similarity. The region between 3.3 and 3.6ppm is very complex for both molecules. It was solved, whenthe identical parts of both molecules were detected. All protons and carbons were unambiguously assigned as shown in (c) and (d), the arrows indicating the NOE's.
Biological Properties
Cymbimicin A binds to cyclophilin A with a high affinity, showing a relative affinity roughly six fold lower terminal ring structures, should be preserved for binding to cyclophilin A. Binding of cymbimicin A and B to cyclophilin isomers B and C was also measured and found similar to the binding to cyclophilin A (Table 3 ).
In T-lymphocytes, binding of cyclosporin to cyclophilin results in an inhibition of calcineurin phosphatase activity11} and subsequent inhibition of T-lymphocyte activation through inhibition of the expression of early activation genes which include the gene coding for lymphokines such as interleukine 2 (IL-2). The ability of the cymbimicin-cyclophilin complexes to inhibit calcineurin phosphatase activity was tested in a cell-free enzymatic assay using a 19 amino acid phospho peptide as substrate12).
Neither of the two cymbimicins (at with an IC50 in the 100nMrange for cyclosporin A. In contrast to cyclosporin A9), cymbimicin A did not inhibit the transcription of the gene coding for IL-2 measured in an IL-2 reporter gene assay (IC50 8.8ng/ml and > 10,000 ng/ml, respectively). Moreover, a high excess of cymbimicin A (up to 1000-fold) was unable to reverse the activity of cyclosporin A in the IL-2 reporter gene assay (data not shown), indicating that it cannot act as an antagonist of cyclosporin. The absence of activity in cellular assays can be due to a lack of cell membrane penetration, cymbimicin A was unable to compete for the binding of 3H cyclosporin A to cells, when added at a molar excess of 30-fold in a cellular uptake assay. Thus, the lack of immuno-suppressive activity of cymbimicin A in cellular assays could be attributed at least in part to the fact that they do not enter the cell.
